Embed Size (px)
Citation preview
PSORIASISPART ONE
Promising Therapeutic Area
JAYDEEP ADHIKARI
Around 3.0 million untreated population in USMore the 100 million affected globallyAround 20% severely affected diagnosed patient with psoriasis
JAK inhibitor
PDE4 inhibitorBrodalumab
IL17 blocker to preventKeratinocyte proliferation
SteroidsVit. D3Immunosuppresant
IL23 mediated T cell proliferation Interleukin blocker
Key Points
Market Value of about USD 3.9 billionProjected growth of USD 7.4 billion by 2020
Topical formulation is most preferred
Top selling product 2014 Marketed Product by Targets
Market ShareEnbrel (Biologic Vs Synthetic product)
Top 3 Psoriasis Brand(4 year historic sales & 4 year forecast)
Average of the top 3 product sales shows compounded annual growth rate of 10%
Around 150 molecule under development which suggest it is an valuable
therapeutic area
3 of the top 10 pharmaceutical majors have heavily invested in Psoriasis
therapeutic area
Pipeline by Development Phase(YTD. Estimate)
Competitive Landscape
Target Pipeline
Average annual deal size > USD400 mn
Max deal range b/w 50 -100 mn
How do we address the needof mild to moderate
psoriasis?
How do we address the needof pediatric population?
